Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

- PMLiVE

US fast-tracks Ebola vaccine trials as outbreak spreads

NIH brings forward human trials as concerns mount

Samsung incentivises African mHealth project with music

Will also offer discounted handsets and tablets to consumers and health workers

- PMLiVE

Merck Serono to offer innovation grants

Will provide funding of €20m for research and med ed projects

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Merck KGaA furthers antibody ambitions in cancer

Signs deal with Mersana to develop antibody-drug conjugates

- PMLiVE

UK biotech Retrogenix appoints Matthew Britiz

He takes up role as North American business development director

- PMLiVE

Merck KGaA drops Ono-partnered multiple sclerosis drug

Decides phase III candidate ceralifimod isn't worth its continued investment

- PMLiVE

Grünenthal launches pain initiatives in Europe

Launches website for patients in Spain and grants German contract to B & F Brüggemann

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links